What happens at the Mounjaro 5 mg dose — and when does it start?

What the SURMOUNT trials tell us about the titration period

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across the full tirzepatide dose range, up to 15 mg. The headline result (around 20 to 21 percent average body-weight reduction at the highest dose) is the figure most people have read about. Less often discussed is what the trial structure reveals about earlier doses: participants worked through 5 mg as part of a steady titration, and meaningful weight reduction was recorded well before the maintenance ceiling was reached.

This matters for anyone starting at 5 mg or arriving there from the 2.5 mg pen. The 2.5 mg starting dose has one job: letting your body adjust to tirzepatide before the therapeutic work begins. Once you reach 5 mg, the medicine is operating at its first genuinely active level. Progress at this point is real, even if slower than it will be later. Patients who find the 2.5 mg pen tolerable often find the step to 5 mg straightforward; those who experience more side effects at 2.5 mg may find a prescriber recommends staying a little longer before moving up.

NICE's appraisal of tirzepatide (TA1026) draws on this same body of evidence in setting out its recommendation. The appraisal notes that patients who do not achieve at least five percent weight loss after six months at the highest tolerated dose should have continuing treatment reviewed, which is a reason to titrate steadily rather than stall at 5 mg indefinitely.

What the 5 mg dose looks like in practice

Each Mounjaro pen covers four weekly injections at a single strength. The 5 mg pen delivers the same dose each time through the KwikPen mechanism, injected subcutaneously into the abdomen, thigh or upper arm, with the site rotated week to week. If you want a quick practical check before your next injection, spend thirty seconds confirming the injection site you used last week so you can rotate correctly this time, it takes less than a minute and reduces localised skin reactions.

Storage follows the same rules across all Mounjaro strengths: refrigerated between 2 and 8°C. The exact window during which the pen can be kept at room temperature before use is specified in the Patient Information Leaflet rather than here, because the SmPC is the authoritative reference and that window should not be guessed at. If you have questions about storage during travel or a fridge failure, the leaflet is the first place to look, and a prescriber or pharmacist is the right person to ask if anything is unclear.

The volume of each injection at 5 mg is sometimes asked about by people who want to cross-check what they are drawing from the pen. The KwikPen is pre-filled and pre-set, so there is nothing to draw up or measure; the pen handles that. Understanding the ml equivalent is mainly useful as a reassurance check rather than a practical step.

Side effects to be aware of at this dose

Gastrointestinal symptoms are the most commonly reported effects across the tirzepatide dose range. Nausea, loose stools, constipation, indigestion and fatigue each appear in the prescribing information and in trial data, and they tend to cluster around starting a new dose or increasing to the next one. For most people they are mild and pass within a week or two of the body adjusting. Eating smaller portions and avoiding very fatty meals can ease nausea during the early weeks at 5 mg.

There are symptoms that do warrant prompt medical attention rather than a wait-and-see approach. Severe abdominal pain, particularly pain that spreads to the back with or without vomiting, should not be dismissed. The MHRA's Drug Safety Update communications have highlighted acute pancreatitis as an infrequent but serious risk associated with GLP-1 medicines, and in January 2026 the MHRA issued specific guidance on this for healthcare professionals. Any sudden or severe pain in the abdomen needs the same-day attention of a doctor, not a prescriber message at the next convenient moment.

Women who take an oral contraceptive pill should be aware that tirzepatide can affect absorption; additional non-oral contraception is recommended for the first four weeks at any new dose, including the step to 5 mg. The NHS guidance on weight-management injections covers this clearly. It is the kind of detail worth raising with a prescriber before the dose increases rather than after. You can read more about what the titration schedule involves on the Mounjaro dosing overview page.

When moving beyond 5 mg is the right next step

A prescriber reviews tolerability and progress before recommending the next dose increase. Staying at 5 mg for longer than one pen cycle is sometimes the right clinical choice, if side effects have been significant, or if someone has only recently started and needs more time. There is no benefit, and some risk, in pushing through a titration faster than the prescriber advises. The schedule is designed around four-week intervals for good reason: it gives the body time to adapt and gives the clinical picture time to become clear.

For people who want to understand what comes after 5 mg, the broader guide to Mounjaro strengths sets out the full six-dose ladder in context. People who are still on the 2.5 mg pen and weighing up what the 5 mg step means can also find specific detail on what to expect at 5 mg as a standalone dose. And if you are tracking costs across the titration, the background to Eli Lilly's UK price changes is worth reading, because per-pen costs shift at higher doses.

If you have not yet started treatment and want to know whether tirzepatide is clinically appropriate for you, the right first step is a consultation with a prescriber. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally on the same day. Check your eligibility and start your free consultation to find out whether Mounjaro is suitable for you.